Headquartered in China, Zeen Health’s vision is to build the world’s leading medical-grade mental health digital therapy platform. The company has two products currently, resleep and Dayshine, focusing on insomnia therapy and emotion management respectively. A Randomized Control Trial (RCT) of resleep, conducted by Peking University First Hospital, showed resleep significantly improved the experimental group’s sleep quality. Zeen Health is currently applying for NMPA approval for resleep and expanding more pipelines, such as the PDT-002 for depression intervention, SDT-002 for breast cancer patients’ psychological intervention and SDT-003 for atopic dermatitis patients’ psychological intervention.